Why did NRSN's EPS remain flat in Q3 2024?

NeuroSense Therapeutics Ltd. (NRSN) experienced a net income loss of $2.15 million in Q3 2024, but the company's stock remained flat at $0.95, with a slight increase of 0.23%. The reasons for the flat EPS in Q3 2024 can be analyzed as follows:

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|NRSN|NRSN.O|NeuroSense|2023 Q4|-1.1746031746031746|-3187000|186|
|NRSN|NRSN.O|NeuroSense|2024 Q1|-84.81532147742818|-5404000|186|
|NRSN|NRSN.O|NeuroSense|2024 Q2|76.49478880965441|-857000|186|
|NRSN|NRSN.O|NeuroSense|2024 Q3|-513.7142857142857|-2148000|186|

1. **Focus on Research and Development**: NeuroSense's PrimeC drug has shown promising results in clinical trials, with a 36% reduction in disease progression and a 43% improvement in survival rates. The company's continued investment in R&D might have impacted its short-term financial performance, including flattening the EPS.
2. **Financial Strategic Moves**: NeuroSense secured a U.S. patent for PrimeC, extending intellectual property protection until 2042. The company also raised $600,000 in a private placement and expected additional proceeds from a securities purchase agreement. These financial moves might have been prioritized over short-term EPS growth.

In conclusion, NeuroSense's focus on R&D and strategic financial moves might have contributed to the flat EPS in Q3 2024.